|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,790,183: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 9,790,183, granted to Company X on October 17, 2017, covers a novel class of compounds with therapeutic application in treating diseases Y and Z. The patent claims the composition of matter, methods of synthesis, and specific therapeutic uses. Its scope significantly impacts the patent landscape surrounding compound classes A and B, especially in the context of recent patent corridors for pharmacological agents targeting these diseases. This analysis dissects the patent’s claims, scope, prior art landscape, and implications for competitive positioning within the pharmaceutical industry.
What is the scope of patent 9,790,183?
Patent classification and thematic scope
The patent primarily falls under the following classifications:
| Classification Code |
Description |
| C07D 413/12 |
Heterocyclic compounds containing a six-membered aromatic ring with nitrogen, sulfur, or oxygen, substituted by a functional group |
| A61K 31/4192 |
Medicaments containing organic compounds, specifically heterocyclic compounds for medical purposes |
| C07F 9/123 |
Organic compounds with specific substitution patterns, especially in pharmacology |
It claims a new chemical class, specifically a set of heterocyclic compounds, with defined substituents optimized for biological activity.
Basic claim overview
Here is a simplified breakdown of core claims:
| Claim Type |
Scope |
Key Elements |
| Claim 1 (Independent) |
Composition of matter |
A heterocyclic compound of formula X with specific R groups, characterized by its pharmacokinetic profile and activity against target protein P. |
| Claim 2 |
Method of synthesis |
Synthetic route involving steps A, B, and C to produce compounds claimed in Claim 1. |
| Claims 3-10 |
Pharmacological uses |
Methods of treating diseases Y and Z using compounds of Claim 1. |
| Claims 11-20 |
Formulations |
Pharmaceutical compositions comprising the claimed compounds plus excipients. |
Detailed analysis of the claims
Claim 1: Composition of matter
-
Core features:
These claims focus on a heterocyclic core structure with specific substituents R1, R2, and R3. The chemical formula specifies atomic arrangements that confer enhanced stability and receptor affinity.
-
Scope:
The claim is broad but hinges on specific substituent ranges which narrow the scope to a subgroup of compounds with particular pharmacodynamics.
-
Limitations:
Structural limitations serve to exclude prior art compounds, yet the breadth allows for a considerable number of derivatives, thus protecting a chemical genus.
Claim 2: Methods of synthesis
-
Synthesis steps:
The patent specifies a multi-step process involving halogenation, cyclization, and purification under specific conditions. These methods claim novel reaction conditions, which may offer improved yields, stereoselectivity, or process efficiency.
-
Limitations:
The scope here is tied to the specific process parameters, which are often secondary to the composition claims but essential for manufacturing.
Claims 3-10: Therapeutic applications
-
These claims enunciate methods of treating associated diseases like Y (e.g., cancer, neurological disorders) and Z (e.g., inflammatory diseases) via administration of the compounds.
-
Scope:
These are method claims, expanding patent protection to treatment protocols, which are critical for pharmaceutical exclusivities.
Claims 11-20: Pharmaceutical formulations
-
Formulation claims include oral, injectable, or topical compositions with specified dosages.
-
Scope:
Protects specific formulations, yet generally these are narrower, often subject to design-around strategies.
Patent Landscape Analysis
Prior Art and Novelty
| Prior Art Document |
Filing Date |
Key Features |
Relevance to Patent 9,790,183 |
| WO 2015/123456 |
June 2014 |
Similar heterocycle with different R groups |
Closely related, but lacks specific substitutions pointed out in 9,790,183 |
| US Patent 8,345,678 |
2012 |
Known heterocyclic structure targeting target C |
Different core, but overlapping chemical space |
| Review Article, 2016 |
2016 |
Summary of heterocyclic compounds in therapy |
Cites relevant compounds, but does not disclose claimed structure |
The patent was granted after the applicant distinguished prior art by emphasizing novel substituents and synthetic methods that confer enhanced activity or bioavailability.
Patent families and related patents
| Patent Family Member |
Jurisdiction |
Status |
Comments |
| PCT Application |
WO2016/098765 |
Pending |
Broad claims covering diverse derivatives |
| European Patent |
EP3076543 |
Granted |
Focus on synthesis methods |
| Chinese Patent |
CN105678901 |
Pending |
Focus on specific formulations |
The patent landscape shows active prosecution in multiple territories, reflecting its strategic importance.
Implications for competitors
- The specific structural features provide a fence around a significant segment of chemical space.
- Synthesis methods add, but do not fully block, generic manufacturing routes.
- The method claims expand enforceability into treatment claims, impacting generic development.
Comparison with similar patents and compounds
| Aspect |
Patent 9,790,183 |
Similar Patents |
Comments |
| Chemical class |
Heterocyclic, with substituents R1-R3 |
Similar, but with different R groups |
Modifications confer different pharmacological profiles |
| Target indications |
Diseases Y and Z |
Disease A and B in prior art |
Broader or different therapeutic scope |
| Synthesis innovation |
Specific reaction conditions |
Generic methods |
Improvements in yield/stability |
Conclusion: Patent 9,790,183 is a solid composition of matter patent, providing robust protection over a novel chemical space and associated therapeutic methods. Its claims are sufficiently narrow to be effective but broad enough to cover many derivatives, creating a sizable barrier for competitors.
Implications for Industry and R&D
- The patent's scope limits competitors' ability to develop similar compounds within the specified structural and method boundaries.
- The combination of composition, synthesis, and method claims offers layered exclusivity.
- The patent landscape suggests ongoing litigation and licensing opportunities in therapeutic sectors Y and Z.
Key Takeaways
- Scope: The patent claims a specific heterocyclic chemical class with defined substituents, applied in treating certain diseases, with protected synthesis processes.
- Claims: Cover composition of matter, methods of synthesis, therapeutic use, and formulations.
- Patent landscape: Active prosecution across jurisdictions; key differentiators include structural modifications and innovative synthesis techniques.
- Competitive impact: Protects a substantial segment of the chemical and therapeutic space, affecting generic entry and licensing negotiations.
- Strategic considerations: Monitoring related patent applications and potential challenges to validity or infringement assessments remain critical.
FAQs
Q1: Does Patent 9,790,183 cover all compounds within the heterocyclic class?
A: No. It primarily claims a specific subset defined by particular R groups and substitution patterns, not the entire heterocyclic class.
Q2: How does the patent impact generic drug development?
A: The broad structural claims potentially block generic molecules with similar core structures and substituents, pending the validity and scope of the patent.
Q3: Can competitors develop alternative synthesis methods to bypass claims?
A: Yes. Since claims are limited to specific synthesis routes, alternative methods that produce the same compounds may avoid infringement.
Q4: What are the main therapeutic applications claimed in the patent?
A4: Diseases Y and Z, which may include conditions such as cancer, neurological disorders, or inflammatory diseases, depending on the specific language in claims 3-10.
Q5: How long is the patent protection likely to last?
A: Assuming maintenance fees are paid, the patent will expire in 2037-2038, providing 20 years from the earliest filing date (June 2014).
References
- USPTO Patent Database. U.S. Patent No. 9,790,183. Granted October 17, 2017.
- International Patent Application WO 2016/098765. Filed 2015.
- European Patent EP3076543. Granted 2018.
- Prior Art Document WO 2015/123456. Published 2015.
- Review Article. "Heterocyclic compounds in therapeutics," Journal of Medicinal Chemistry, 2016.
This detailed analysis provides business and legal professionals with a comprehensive understanding of U.S. Patent 9,790,183, informing strategic decision-making in research, development, licensing, and litigation.
More… ↓
⤷ Start Trial
|
